Genenta Science announced that the U.S. FDA has granted Orphan Drug Designation to Temferon for the treatment of glioblastoma multiforme.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GNTA:
- FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
- Genenta Science treatment of glioblastoma multiforme gets FDA orphan status
- Genenta, AGC Biologics enter development, manufacturing service agreement
- Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
- Genenta Science initiated with a Buy at EF Hutton